share_log

Galecto Expected Upcoming Milestones; Top-Line Results From Phase 2b GALACTIC-1 Trial In Mid-2023; Interim Safety Data From Phase 2a GALLANT-1 Trial By Q1 2023; Initiation Of Phase 2 Investigator-Initiated GB1211 Oncology Trial in 2023

Benzinga Real-time News ·  Nov 8, 2022 22:21

Expected Upcoming Milestones

  • Top-line results from Phase 2b GALACTIC-1 trial (IPF) in mid-2023.
  • Interim safety data from Phase 2a GALLANT-1 trial (NSCLC) by Q1 2023.
  • Initiation of Phase 2 investigator-initiated GB1211 oncology trial (melanoma and HNSCC) by Providence Cancer Institute in 2023.
"The recent release of positive results from two clinical trials, our Phase 1b/2a GULLIVER-2 trial in decompensated liver cirrhosis and our Phase 2a MYLOX-1 trial in myelofibrosis, has created significant momentum for Galecto and our team," said Galecto CEO Hans T. Schambye, M.D., Ph.D. "Galectin-3 and LOXL2 play a central role in fueling key pathological pathways in fibrosis, and the encouraging results from both of these trials provides further evidence and strengthens our belief that the inhibition of galectin-3 and LOXL2 are crucial to reducing fibrosis and potentially modifying disease. We look forward to 2023, where we expect to announce top-line results from our Phase 2b GALACTIC-1 trial in idiopathic pulmonary fibrosis (IPF) in mid-2023 and our Phase 2a GALLANT-1 trial in non-small cell lung cancer (NSCLC) in the second half of 2023."
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment